Analytical Data
-
Gene name
LILRB4/CD85k/ILT3
- Application
-
Alternative Names
HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAH26309.1
-
Expression Region
Q22-E259
-
Molecular Weight
60-66 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRB4, also known as CD85k or ILT3 (Immunoglobulin-like transcript 3), is a member of the leukocyte immunoglobulin-like receptor (LILR) family, which plays a crucial role in regulating immune responses. This receptor is predominantly expressed on myeloid cells, including dendritic cells and macrophages, and is involved in inhibitory signaling pathways that modulate T cell activation and maintain immune tolerance. Its significance has been underscored in various studies linking LILRB4 to processes such as tumor immune evasion, autoimmune diseases, and chronic infections. The expression of LILRB4 on tumor-associated macrophages facilitates the suppression of anti-tumor immunity, making it a subject of interest in cancer immunotherapy. Additionally, recombinant LILRB4/CD85k/ILT3 proteins have been developed for research purposes to better understand their structural and functional properties, as well as their interactions with ligands. Investigating the role of this receptor can provide insights into novel therapeutic targets for modulating immune responses and enhancing the efficacy of immunotherapies. Understanding the mechanisms through which LILRB4 operates not only aids in deciphering its biological functions but also paves the way for novel approaches to address immune-related disorders.
